Statement of Principles
centering
MICROSCOPIC POLYANGIITIS
(Reasonable Hypothesis)
(No. 90 of 2019)

The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.

Dated 18 October 2019

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

[Signature]

Professor Nicholas Saunders AO
Chairperson
1 **Name**
This is the Statement of Principles concerning *microscopic polyangiitis (Reasonable Hypothesis)* (No. 90 of 2019).

2 **Commencement**
This instrument commences on 18 November 2019.

3 **Authority**
This instrument is made under subsection 196B(2) of the *Veterans' Entitlements Act 1986*.

4 **Repeal**
The Statement of Principles concerning microscopic polyangiitis No. 13 of 2011 (Federal Register of Legislation No. 2010L03260) made under subsection 196B(2) of the VEA is repealed.

5 **Application**
This instrument applies to a claim to which section 120A of the VEA or section 338 of the *Military Rehabilitation and Compensation Act 2004* applies.

6 **Definitions**
The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.

7 **Kind of injury, disease or death to which this Statement of Principles relates**

   (1) This Statement of Principles is about microscopic polyangiitis and death from microscopic polyangiitis.

   **Meaning of microscopic polyangiitis**

   (2) For the purposes of this Statement of Principles, microscopic polyangiitis:

       (a) means a necrotising non-granulomatous vasculitis with few or no immune deposits predominantly affecting small vessels (capillaries, venules or arterioles); and
       (b) excludes polyarteritis nodosa, granulomatosis with polyangiitis (Wegener granulomatosis) and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

   Note: Microscopic polyangiitis commonly manifests in the kidney as rapidly progressive crescentic glomerulonephritis, or in the lungs as pulmonary capillaritis. Antineutrophil cytoplasmic antibodies (ANCA) are usually present.
(3) While microscopic polyangiitis attract ICD-10-AM code M31.7, in applying this Statement of Principles the meaning of microscopic polyangiitis is that given in subsection (2).


Death from microscopic polyangiitis

(5) For the purposes of this Statement of Principles, microscopic polyangiitis, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's microscopic polyangiitis.

Note: *terminal event* is defined in the Schedule 1 – Dictionary.

8 Basis for determining the factors

The Repatriation Medical Authority is of the view that there is sound medical-scientific evidence that indicates that microscopic polyangiitis and death from microscopic polyangiitis can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.

Note: *MRCA*, *relevant service* and *VEA* are defined in the Schedule 1 – Dictionary.

9 Factors that must exist

At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting microscopic polyangiitis or death from microscopic polyangiitis with the circumstances of a person's relevant service:

(1) inhaling respirable crystalline silica dust, at the time material containing crystalline silica was being:
   (a) produced;
   (b) excavated;
   (c) drilled, cut or ground; or
   (d) used in construction, manufacturing, cleaning or blasting;
   for a cumulative period of at least 2 500 hours before the clinical onset of microscopic polyangiitis;

(2) having silicosis at the time of the clinical onset of microscopic polyangiitis;
(3) being treated with a drug from the specified list of drugs at the time of the clinical onset of microscopic polyangiitis;

Note: specified list of drugs is defined in the Schedule 1 - Dictionary.

(4) inhaling respirable crystalline silica dust, at the time material containing crystalline silica was being:

(a) produced;
(b) excavated;
(c) drilled, cut or ground; or
(d) used in construction, manufacturing, cleaning or blasting;

for a cumulative period of at least 2,500 hours before the clinical worsening of microscopic polyangiitis;

(5) having silicosis at the time of the clinical worsening of microscopic polyangiitis;

(6) being treated with a drug from the specified list of drugs at the time of the clinical worsening of microscopic polyangiitis;

Note: specified list of drugs is defined in the Schedule 1 - Dictionary.

(7) inability to obtain appropriate clinical management for microscopic polyangiitis.

10 Relationship to service

(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.

(2) The factors set out in subsections 9(4) to 9(7) apply only to material contribution to, or aggravation of, microscopic polyangiitis where the person's microscopic polyangiitis was suffered or contracted before or during (but did not arise out of) the person's relevant service.

11 Factors referring to an injury or disease covered by another Statement of Principles

In this Statement of Principles:

(1) if a factor referred to in section 9 applies in relation to a person; and

(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;

then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.
1 Definitions

In this instrument:

Microscopic Polyangiitis—see subsection 7(2).


relevant service means:
(a) operational service under the VEA;
(b) peacekeeping service under the VEA;
(c) hazardous service under the VEA;
(d) British nuclear test defence service under the VEA;
(e) warlike service under the MRCA; or
(f) non-warlike service under the MRCA.

Note: MRCA and VEA are also defined in the Schedule 1 - Dictionary.

specified list of drugs means:
(a) benzylthiouracil;
(b) carbimazole;
(c) hydralazine;
(d) methimazole; or
(e) propylthiouracil.

Terminal event means the proximate or ultimate cause of death and includes the following:
(a) pneumonia;
(b) respiratory failure;
(c) cardiac arrest;
(d) circulatory failure; or
(e) cessation of brain function.

VEA means the Veterans’ Entitlements Act 1986.